


What is claimed is:

1. A compound of Formula (I)



or a pharmaceutically acceptable salt or solvate thereof

wherein

A^1 and A^2 are each independently C_{1-4} alkylene or a bond;

A^3 is C_{1-4} alkylene or C_{1-4} alkylidene;

A^4 is C_{1-4} alkylene or a bond and is attached to X, X^1 or X^2 ;

X, X^1 , X^2 and X^3 are independently C or CH;

J is C_{1-4} alkyl;

p is 0 or 1;

R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O- C_{1-4} alkyl or C_{1-4} alkyl-N(H)C(O)O-;

said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolynyl, imidazolidinyl, pyrazolyl, pyrazolynyl, pyrazolidinyl,

pyridyl, pyrimidinyl, piperidinyl, piperazinyl,
 morpholino, adamantyl, indolyl, isoindolyl, indolinyl,
 quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl,
 isoquinolinyl, dihydroisoquinolinyl and
 tetrahydroisoquinolinyl, wherein said heterocyclic
 moieties are optionally substituted with halo, C₁₋₄alkyl,
 C₁₋₄alkoxy or cyano;

or wherein -A¹-R¹ and -A²-R² together with the nitrogen to
 which they are attached form pyrrolyl, pyrrolinyl,
 pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl,
 pyrazolyl, pyrazoliny, pyrazolidinyl, pyridyl,
 pyrimidinyl, piperidinyl, piperazinyl, morpholino,
 adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl,
 dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,
 dihydroisoquinolinyl or tetrahydroisoquinolinyl and are
 optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy,
 cyano or benzyl;

R³ is H or C₁₋₄alkyl;

m is 0 or 1;

R⁴ and R⁵ are independently hydrogen, cyano, halo, nitro or C₁₋₃perfluoroalkyl;

wherein said R⁴ or R⁵ may be independently attached to X, X¹,
 X² or X³;

n is 0 or 1;

G is N, O or S;

G¹ is N or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

both R^4 and R^5 are not attached to the same of said X, X^1 , X^2 or X^3 ;

if G is O or S, then m is 0;

if G is N, then m is 1;

5 if R^1 is $-N(H)C(O)OC_{1-4}alkyl$, $C_{1-4}alkyl-N(H)C(O)O-$ or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^1 , then A^1 is $C_{2-4}alkylene$;

10 if R^2 is $-N(H)C(O)OC_{1-4}alkyl$, $C_{1-4}alkyl-N(H)C(O)O-$ or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2 , then A^2 is $C_{2-4}alkylene$;

15 if R^1 is $N(H)C(O)O-C_{1-4}alkyl$, $C_{1-4}alkyl-N(H)C(O)O-$ or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, 20 dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}alkyl$, $C_{1-4}alkoxy$ or cyano, then R^2 is H or $C_{1-3}alkyl$;

25 if R^2 is $-N(H)C(O)O-C_{1-4}alkyl$, $C_{1-4}alkyl-N(H)C(O)O-$ or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, 30 piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl,

dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R¹ is H or C₁₋₃alkyl;

if A⁴, R⁴ or R⁵ are attached to X, then X is C;

if A⁴, R⁴ or R⁵ are attached to X¹, then X¹ is C;

if A⁴, R⁴ or R⁵ are attached to X², then X² is C;

if R⁴ or R⁵ are attached to X³, then X³ is C;

if R⁴ is F and is attached to X and if A³ is methylene, then -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached is not N-methyl-piperazinyl; and

if R⁴ is F and is attached to X and if A³ is methylene, then -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached is not tetrahydroquinolinyl.

2. A compound according to claim 1 wherein p is 0.
3. A compound according to claim 1 wherein G is N and G¹ is CH.
4. A compound according to claim 1 wherein G is S and G¹ is CH.
5. A compound according to claim 1 wherein G is N and G¹ is N.
6. A compound according to claim 1 wherein A¹ is a bond, R¹ is methyl, A² is a bond and R² is methyl.
7. A compound according to claim 1 wherein R³ is H and m is 1.
8. A compound according to claim 1 wherein R⁴ and R⁵ are halo.
9. A compound according to claim 1 wherein R⁴ is hydrogen.
10. A compound according to claim 1 wherein R⁴ is fluoro.
11. A compound according to claim 1 wherein R⁴ is cyano.
12. A compound according to claim 1 wherein R⁴ and R⁵ are each fluoro.
13. A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of S; and wherein

the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.

14. A compound according to claim 1 wherein A³ is C₁₋₄alkylene.
15. A compound according to claim 1 wherein A³ is C₁₋₄alkylidene.
- 5 16. A compound according to claim 1 wherein A³ is methylene.
17. A compound according to claim 1 wherein A⁴ is a bond.
18. A compound according to claim 1 wherein A⁴ is methylene.
19. A compound according to claim 1 wherein A⁴ is attached X¹.
20. A compound according to claim 1 wherein A⁴ is attached X.
- 10 21. A compound according to claim 1 wherein R⁴ is attached X.
22. A compound according to claim 1 wherein A¹ is a bond, A² is a bond, R¹ is methyl and R² is methyl.
23. A compound according to claim 1 wherein R¹ is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolynyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano; A¹ is C₁₋₄alkylene; R² is H or C₁₋₃alkylene; and A² is a bond.
- 15 24. A compound according to claim 1 wherein R¹ is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl; A¹ is C₁₋₄alkylene; R² is H or C₁₋₃alkylene; and A² is a bond.
- 20 25. A compound according to claim 1 wherein R² is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolynyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally
- 25 30

substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano; A² is C₁₋₄alkylene; R¹ is H or C₁₋₃alkylene; and A¹ is a bond.

26. A compound according to claim 1 wherein R² is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny; A² is C₁₋₄alkylene; R¹ is H or C₁₋₃alkylene; and A¹ is a bond.
27. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C₁₋₄alkyl.
28. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, or -N(H)C(O)O-C₁₋₄alkyl.
29. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, or -O-phenyl.
30. A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
31. A compound according to claim 1 wherein R² is H or C₁₋₃alkyl and R¹ is C₃₋₆cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C₁₋₄alkyl.
32. A compound according to claim 1 wherein R² is H or C₁₋₃alkyl and R¹ is N(H)C(O)O-C₁₋₄alkyl.
33. A compound according to claim 1 wherein R² is H or C₁₋₃alkyl and R¹ is C₃₋₆cycloalkyl, phenyl or -O-phenyl.
34. A compound according to claim 1 wherein R² is H or C₁₋₃alkyl and R¹ is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.
35. A compound according to claim 1 wherein R¹ is H or C₁₋₃alkyl and R² is C₃₋₆cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C₁₋₄alkyl.
36. A compound according to claim 1 wherein R¹ is H or C₁₋₃alkyl and R² is N(H)C(O)O-C₁₋₄alkyl.
37. A compound according to claim 1 wherein R¹ is H or C₁₋₃alkyl and R² is C₃₋₆cycloalkyl, phenyl or -O-phenyl.

38. A compound according to claim 1 wherein wherein R^1 is H or C_{1-3} alkyl and R^2 is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidiny, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny.

5 39. A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidiny, piperidiny, piperazinyl, morpholino, adamantyl, tetrahydroquinoliny or tetrahydroisoquinoliny and are optionally substituted with benzyl.

40. A compound according to claim 1 wherein

10 A^1 and A^2 are each independently C_{1-4} alkylene or a bond;

A^3 is C_{1-4} alkylene;

A^4 is a bond and is attached to X or X^1 ;

R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl or -N(H)C(O)O- C_{1-4} alkyl;

15 said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo;

20 or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidiny, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinoliny and tetrahydroisoquinoliny;

25 or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidiny, piperidiny, piperazinyl, morpholino, adamantyl, tetrahydroquinoliny or tetrahydroisoquinoliny and are optionally substituted with benzyl;

R^3 is H or C_{1-4} alkyl;

m is 0 or 1;

30 R^4 is cyano or halo and is attached to X or X^1 ;

n is 0;

X and X¹ are each C;

X² and X³ are each CH;

G is N, O or S;

5 G¹ is N or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

if G is O or S; then m is 0;

10 if G is N, then m is 1;

if R¹ is -N(H)C(O)OC₁₋₄alkyl or said heterocyclic moiety
wherein said heterocyclic moiety contains a nitrogen
atom and said nitrogen atom is attached to A¹, then A¹
is C₂₋₄alkylene;

15 if R² is -N(H)C(O)OC₁₋₄alkyl or said heterocyclic moiety
wherein said heterocyclic moiety contains a nitrogen
atom and said nitrogen atom is attached to A², then A²
is C₂₋₄alkylene;

20 if R¹ is -N(H)C(O)O-C₁₋₄alkyl or said heterocyclic moiety,
then R² is H or C₁₋₃alkyl;

if R² is -N(H)C(O)O-C₁₋₄alkyl or said heterocyclic moiety,
then R¹ is H or C₁₋₃alkyl;


25 if R⁴ is F and is attached to X and if A³ is methylene, then -
A¹-R¹ and -A²-R² together with the nitrogen to which
they are attached is not N-methyl-piperazinyl; and

if R⁴ is F and is attached to X and if A³ is methylene, then -A¹-
R¹ and -A²-R² together with the nitrogen to which they
are attached is not tetrahydroquinolynyl.


41. *Trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane; *Trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclopropane; *Trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-benzylaminomethyl]-cyclopropane; (1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane;
- 5 (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-1-(*N*-Benzlyaminomethyl) -2-[5-cyanoindol-3-yl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-3-phenylpropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(3-indolyl)ethylaminomethyl]-cyclopropane; *trans*-1-(4-Benzyl-piperidin-1-ylmethyl)-2-[5-cyanoindol-3-yl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-dipropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-phenylethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-phenylethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(2-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(3-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-(4-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N*-2-phenoxy-ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[pyrrolidin-1-yl-methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(methylcarbamoyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(ethylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(propyl carbamoyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(methylcarbamoyl)propyl aminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-ethyl-2-amino(ethylcarbamoyl)propylaminomethyl]-cyclopropane; *Cis*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane; (1*S*,2*S*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(*N*-methylaminomethyl)cyclopropane; *trans*-3-[2-(1-Dimethylamino-ethyl)-cyclopropyl]-1*H*-indole-5-carbonitrile; *trans*-3-[2-(1-Pyrrolidin-1-yl-ethyl)-cyclopropyl]-1*H*-indole-5-carbonitrile; (-)*Cis*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-
- 10
- 15
- 20
- 25
- 30

dimethylaminomethyl)cyclopropane; 5-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile; [2-(5,6-Difluoro-1H-indol-3-yl)-cyclopropylmethyl]-dimethyl-amine; *Trans*-2-[5-cyanoindol-3-yl]-1-(3-(N-methylamino)propyl)cyclopropane; S,S-*Trans*-2-[5-Cyanoindol-3-yl]-1-(trimethylammoniummethyl)cyclopropane trifluoroacetate; S,S-*trans*-2-[5-cyano-1-methylindol-3-yl]-1-(N,N-dimethylamino)-cyclopropane; S,S-*trans*-2-[5-cyano-1-ethylindol-3-yl]-1-(N,N-dimethylamino)-cyclopropane; or 6-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile or pharmaceutically acceptable salts or solvates thereof.


42. A pharmaceutically acceptable formulation comprising a compound according to claim 1.
43. A method of treating depression, anxiety disorders, premature ejaculation, urinary incontinence, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, hot flashes, panic disorders, posttraumatic stress disorder or social phobia comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
44. A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
45. A process for the preparation of a compound of Formula (d)



by reacting a compound of formula (b)




with a compound of formula (c)




in the presence of ethyl diazoacetate and toluene, wherein R^4 is cyano, halo, nitro or C_{1-3} perfluoroalkyl and X is *p*-toluenesulfonyl, benzenesulfonyl, methanesulfonyl or trifluoromethanesulfonyl.


46. According to another embodiment of the eleventh aspect of the present invention is provided a process for the preparation of a compound of Formula (d')



by reacting a compound of formula (b)



with a compound of formula (c)



5

in the presence of tert-butyl diazoacetate and toluene, wherein R^4 is cyano, halo, nitro or C_{1-3} perfluoroalkyl and X is *p*-toluenesulfonyl, benzenesulfonyl, methanesulfonyl or trifluoromethanesulfonyl.

- 10 47. A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound according to claim 1 and an erectile dysfunction agent.
48. A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound
- 15 according to claim 1 and sildenafil.